-
Electronic (PDF)
-
Site License
-
Enterprisewide
Advanced Cell Technology, Inc. (ACTC) - Financial and Strategic SWOT Analysis Review
GlobalData, August 2011, Pages: 41
Advanced Cell Technology, Inc. (ACTC) - Financial and Strategic SWOT Analysis Review
Summary
Advanced Cell Technology, Inc. (ACT) is a publicly traded biotechnology company, specializes in cellular therapies for the treatment of rare and common diseases. In addition, it is engaged in the development and commercialization of human embryonic stem cell technology in the field of regenerative medicine. The company focuses on developing and commercializing embryonic stem (ES) cell based technologies and adult stem cell transplantation therapies, targeting the heart and other cardiovascular diseases. The company's key projects under development include Myoblast program, Retinal Pigment Epithelium (RPE) program and Hemangioblast (HG) cell program. ACT is headquartered at Marlborough in Massachusetts, the US.
Advanced Cell Technology, Inc. Key Recent Developments…
May 09, 2011 Advanced Cell Technology Reports Net Loss Of $3.3m For Q1 2011
Mar 23, 2011 Advanced Cell Technology To Receive Patent For Human ES Cell-Derived RPE Cells In China
Feb 23, 2011 ACT Secures Patent To Generate Embryonic Stem Cells Without Embryo Destruction
Nov 11, 2010 Advanced Cell Technology Reports Net Income Of $1.9 Million For Q3 2010
Nov 02, 2010 Advanced Cell Technology Receives Federal Grant Of Nearly $1 Million
This comprehensive SWOT profile of Advanced Cell Technology, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
Advanced Cell Technology, Inc. - Key Facts
Advanced Cell Technology, Inc. - Key Employees
Advanced Cell Technology, Inc. - Key Employee Biographies
Advanced Cell Technology, Inc. - Major Products and Services
Advanced Cell Technology, Inc. - Pharmaceutical Pipeline Products Data
Advanced Cell Technology, Inc., Pipeline Products by Therapy Area
Advanced Cell Technology, Inc., Pipeline Products by Development Phase
Advanced Cell Technology, Inc. - History
Advanced Cell Technology, Inc. - Company Statement
Advanced Cell Technology, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Advanced Cell Technology, Inc. - Business Description
Advanced Cell Technology, Inc. - SWOT Analysis
SWOT Analysis - Overview
Advanced Cell Technology, Inc. - Strengths
Strength - Strong In-house Research Expertise
Strength - Patent Portfolio
Advanced Cell Technology, Inc. - Weaknesses
Weakness - Legal Proceedings
Weakness - Limited Liquidity Position
Weakness - Declining Operating Margin
Weakness - Declining Market Share in Sector
Advanced Cell Technology, Inc. - Opportunities
Opportunity - Organic Growth Drivers: Agreements & Collaboration
Opportunity - Orphan Drug Designation for RPE Cells
Opportunity - Market Potential: Age-related Macular Degeneration
Opportunity - Potential Market: Heart Failure
Opportunity - Changing Demographics
Advanced Cell Technology, Inc. - Threats
Threat - Dependence on Emerging Technologies
Threat - Stringent Government Regulations
Threat - Increasing Competitive Pressures
Threat - Uncertain R&D Outcomes
Advanced Cell Technology, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Advanced Cell Technology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Advanced Cell Technology, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Advanced Cell Technology, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
May 09, 2011: Advanced Cell Technology Reports Net Loss Of $3.3m For Q1 2011
Mar 23, 2011: Advanced Cell Technology To Receive Patent For Human ES Cell-Derived RPE Cells In China
Feb 23, 2011: ACT Secures Patent To Generate Embryonic Stem Cells Without Embryo Destruction
Nov 11, 2010: Advanced Cell Technology Reports Net Income Of $1.9 Million For Q3 2010
Nov 02, 2010: Advanced Cell Technology Receives Federal Grant Of Nearly $1 Million
Sep 14, 2010: Advanced Cell Technology Obtains Broad Patent Covering Use Of Stem Cell-Derived RPE Cells To Treat Eye Disorders
Aug 30, 2010: Advanced Cell Technology Provides Update On Transdifferentiation Platform In Regenerative Medicine
Aug 16, 2010: ACT Poised To Obtain And Control Key Patents To Generating iPS Cells
Aug 16, 2010: ACT Poised To Obtain And Control Patents To Generating iPS Cells
Aug 08, 2010: Advanced Cell Technology Reports Net Income Of $2.9 Million For Q2 2010
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Genzyme Corporation
StemCells, Inc.
ViaCord
Osiris Therapeutics, Inc.
Bioheart, Inc.
Aastrom Biosciences, Inc.
Geron Corporation
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
